Skip to content
You are now leaving to visit

Ionis to Independently Advance Inotersen and IONIS-FB-L Rx

Inotersen on Track for Marketing Authorization Filings This Year Conference Call Webcast Friday, August 11, 8:30 a.m. ET at CARLSBAD, Calif. , Aug. 11, 2017 /PRNewswire/ —  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today reported that the Company has retained all rights to